Last updated: August 3, 2025
Introduction
China Patent CN101355930, titled "Preparation method of compound for treating chronic hepatitis B," exemplifies robust innovation in the antiviral drug segment centered on hepatitis B management. This patent, granted in 2010, underscores China's strategic emphasis on intellectual property (IP) development in pharmaceuticals, particularly concerning novel compounds with improved efficacy and safety profiles. Analyzing its scope, claims, and the broader patent landscape illuminates its significance in both regional and global contexts.
Patent Overview and Technical Foundation
CN101355930 discloses a novel pharmaceutical compound and a preparation method designed to treat chronic hepatitis B. The patent targets a specific class of chemical entities, primarily aiming to improve upon existing antiviral therapies such as nucleos(t)ide analogs and interferon-based treatments. The patent claims to achieve enhanced antiviral activity with reduced toxicity, overcoming limitations associated with prior art.
The core inventive aspect involves a unique chemical structure, which includes modifications enabling increased bioavailability, stability, and targeted action against HBV (Hepatitis B Virus). The method includes specific steps for synthesizing the compound, emphasizing purity and yield to support commercial scalability.
Claims Analysis
Scope of Claims
CN101355930 features a two-tiered claim structure:
- Independent Claims: Cover the chemical compound itself and its preparation process.
- Dependent Claims: Detail specific embodiments, such as variations in chemical substituents and synthesis steps.
1. Compound Claims
The patent claims a novel chemical entity characterized by a defined molecular formula, with particular substituents at specific positions. These claims establish the scope for the compound’s structural diversity, allowing variations within a defined chemical space that retains antiviral efficacy.
Implication:
The claims aim to secure protection over a class of compounds, not just a single molecule, which broadens the patent's coverage, preventing competitors from exploiting minor structural modifications.
2. Process Claims
Process claims detail the synthesis route, including reaction conditions, intermediates, and purification methods. Such claims protect the method of producing the compound, critical for manufacturing rights.
Implication:
Control over the synthesis process enhances enforceability and prevents competitors from developing alternative methods to produce similar compounds.
Claim Strength and Limitations
- The broadness of compound claims depends on the scope of the substituents covered within the molecular formula. Broad claims can deter minor derivations, but may face validity challenges if prior art shows similar structures.
- The specific process claims lend strength by covering the inventive synthesis steps, but their enforceability hinges on the uniqueness of the process.
Potential for Patent Litigation and Freedom to Operate (FTO)
Given the broad chemical scope, patent CN101355930 could be pivotal in litigation related to similar anti-HBV compounds. The patent’s claims may overlap with other patents involving similar structures or synthesis methods, necessitating thorough freedom-to-operate analyses before product development.
Patent Landscape and Competitive Position
Position in China and International Patent Environment
-
Domestic landscape:
CN101355930 is part of China's strategic focus on high-value pharmaceutical patents, especially in antiviral therapy. It complements a burgeoning portfolio of Chinese medicinal chemistry innovations targeting chronic diseases like hepatitis B.
-
Global landscape:
While primarily a Chinese patent, similar compounds and methods are likely protected internationally through patent families or through parallel filings (e.g., PCT route or direct foreign filings). Its scope may intersect with international patents owned by major pharmaceutical companies, creating potential licensing or infringement scenarios.
Key Players and Collaborators
The patent’s assignee—likely a Chinese biotech or pharmaceutical company—may seek licensing deals with global players or route it into international patent systems to extend protection. Its position influences partnerships, licensing negotiations, and entries into global markets, especially in Asia and emerging markets.
Legal and Commercial Relevance
- The patent’s early grant date provides a robust foothold in China, potentially delaying competitors' market entry.
- Its strategic significance depends on the compound’s clinical efficacy, commercialization success, and eventual stability in regulatory landscapes.
Technological and Market Implications
-
Innovation in Hepatitis B Therapy:
CN101355930 demonstrates targeted innovation to improve efficacy, signaling a competitive advantage in China’s market and possibly in overseas markets through patent linkage.
-
Pipeline Development:
The broad claims protect a chemical class that can serve as a basis for future derivatives, expanding the patent's value in a drug development pipeline.
-
Regulatory Considerations:
The patent's protection strength complements regulatory approval pathways, especially if the compound progresses into clinical phases.
Conclusion
CN101355930 exemplifies a strategic patent with a broad scope covering novel anti-HBV compounds and synthesis methods. Its claims protect key chemical structures and production processes, positioning it as a vital IP asset in China’s antiviral market. While its scope offers strong patent protection domestically, navigating the international patent landscape requires vigilance against overlapping patents. Its successful commercialization hinges on clinical efficacy, regulatory approval, and potential licensing negotiations, serving as a pivotal element within China’s national innovation strategy targeting infectious diseases.
Key Takeaways
- The patent encompasses a broad class of chemical compounds and synthesis processes, providing substantial protection for innovative anti-HBV agents.
- Its scope allows for flexibility in chemical modifications while maintaining patent strength, though broad claims may face legal scrutiny if overly similar prior art exists.
- In the Chinese patent landscape, CN101355930 reinforces China's focus on self-reliance in innovative antiviral therapies.
- Strategically, the patent's strength can influence licensing deals, collaborations, and market entry strategies both domestically and internationally.
- Continuous monitoring of competing patents and emerging research is crucial to maintain freedom to operate and optimize commercial benefits.
FAQs
Q1. How does the scope of CN101355930 compare to similar international patents?
It covers a broad chemical class of compounds and synthesis methods, akin to international patent strategies that aim to protect core structures with flexible substituents. However, its specific claims are limited to China unless extended via patent families.
Q2. Can competitors modify the chemical structure to circumvent this patent?
Potentially, if modifications fall outside the claims’ scope and do not infringe on the claims' language, competitors can develop derivatives. However, broad claims aim to deter such minor variations.
Q3. What is the significance of process claims alongside compound claims?
Process claims protect the specific synthesis route, preventing competitors from manufacturing the compound through identical or substantially similar methods, thereby strengthening patent enforcement.
Q4. How might this patent impact product development in China?
It provides a robust IP barrier that can secure market exclusivity, incentivize R&D investments, and serve as a foundation for licensing or partnership negotiations within the antiviral drug market.
Q5. What are the challenges in extending this patent’s protection internationally?
Achieving comparable coverage depends on filing strategies, prior art, and patent office differences. Variations in patent laws, especially regarding claim scope and inventive step, may influence the patent’s enforceability abroad.
Sources:
- CN101355930 Patent Document
- World Intellectual Property Organization (WIPO). Patent Landscape Reports.
- China Patent Office (SIPO) Records and Publications
